Universal Oral Vaccine: The Immune Milk Saga

by Anthony di Fabio
(continued from last issue)

Stolle Milk Biologics International
Beck and Zimmerman,* divide the history of immune milk discoveries into two general eras:

(1) The Peterson Era (1950-1958) where Drs. “Pete” Peterson, Barry Campbell, and colleagues at the University of Minnesota used killed bacterial antigens injected into the teat of a cow, and collected the first ten days’ colostrum, as, after the tenth day milk antibodies were almost entirely absent for immunization purposes.

“Peterson’s interest in human diseases was concentrated on rheumatoid arthritis and allergies. . . .”38

Peterson’s work, and its acceptance by the scientific community, was greatly limited by the state of knowledge of immunology of the times, according to Dr. Beck.

Impro Products of Waukon, Iowa received licenses from Peterson, and went on to file some of the early patents, also supplying to this day a variety of products for use as a veterinarian product.

(2) The Stolle Era (1958 to present) began with Ralph Stolle, businessman and owner-operator of the SanMarGale Farm in Lebanon, Ohio.

Ralph Stolle was a businessman with far-reaching vision, who built his financial empire upon innovation, and who was drawn to the concept of immune milk by the work being performed by Dr. Peterson and colleagues.

Stolle early concluded that the Peterson method of introducing antigens through the bovine’s teats had commercial drawbacks, and he set out to develop new methods that would permit system-wide standardization of the vaccination of antigens, separation of antibodies and other transfer factors, their safe storage and later use by humans.

That Stolle Biologics International and their team of scientists -- Lee R. Beck, Ph.D., President, Daniel A. Gingerich, D.V.M., M.S., Peter Fuhrer, Ph.D., Director of Biochemistry, Robert Stohrer, Ph.D., Associate Director Biotechnology Division, and others -- were successful is testified to by the more than 300 patents granted to Stolle Biological. These patents cover methods of production and composition of immune milk, isolation of anti-inflammatory factors, methods for treating vascular and pulmonary systems, prevention and treatment of arthritis, treating protozoal gastrointestinal disorders, production of immune suppressive product, passive immunization of mammals using avian and/or bovine antibodies, antibodies derived from bovid milk and avian egg, general mammalian immunization, dental caries inhibiting products, deodorants containing antibacterial antibodies, longevity factors, prevention of suppression of t-lymphocyte functions, protein antibodies derived from bovid serum, and use of honey as a vaccine.

These patents were filed and granted in the United States as

(continued on page 2)

Lee R. Beck, Ph.D. has 26 years of research and business experience in the field of milk biologics. His earliest work was as Director of Reproductive Research at the University of Alabama, Birmingham Medical School, directing a staff of 15 scientists, and where he was a pioneer in the field of controlled drug delivery. Dr. Beck worked as a consultant to the Stolle Research & Development Corporation from 1972 to 1985, also working with Mr. Ralph Stolle to manage and build Stolle’s research laboratory becoming Executive Vice President and Director of Research for Stolle R & D in 1985. He became President of Stolle Milk Biologics International in 1995 when Stolle R & D and the New Zealand Dairy Board formed the Stolle Milk Biologics International venture. Photo taken Blue Ash, Ohio, 1998.
December 13, 1997, “S100” was the designation for specially prepared milk to be tested. In the study referenced by the Japanese Rheumatism association, using double-blind procedures, arthritis scores were highest in the control group, with arthritis symptoms significantly reduced ($p<0.05$) in all immune milk groups. Information and sketches obtained from Stolle Milk Biologics International, Blue Ash, OH.

Cows are inoculated using standardized vaccines containing known antibodies. The cream is drawn from the milk from which ice cream and butter are made. Skim milk is then processed further by addition of rennet to produce casein, cheese and whey.

Whey is further separated by ultrafiltration into “Whey Protein Concentrate” (containing high molecular weight proteins and IgG antibodies) and “permeate” (containing low molecular weight proteins and anti-inflammatory factors).
Universal Oral Vaccine: The Immune Milk Saga

The permeate is run through an ion exchange column washed with 0.15 Moles NaCl, then freeze dried.

Permeate and antibodies are combined together after removing the lactose from the permeate, producing "Whey Protein Isolate," a product that is spray dried and sold as a commercial product.

Numerous research studies clearly show that the Stolle products have desirable impact on strengthening the immune system, but of course, none are aimed at solving a specific disease condition, such as Lyme arthritis disease, surely the next great commercial step in the immune history saga.

Dr. Struss reports that a method other than rennet was used by original researchers. This was glacial acetic acid. They found that the agglutinating titers were higher than when using rennet, which is a proteolytic enzyme. This resulted in a larger quantity of specific antibodies and complement. When using only rennet, the casein had to be washed out or dissolved to obtain its entrapped antibodies/complements.

In a trip to New Zealand (1999), Herbert Struss, Ph.D. reports that two kinds of colostrum are produced, disease specific and non-specific colostrum.

Background and Summary
Partial List of Publications, Studies and Patents
Except for an abandoned patent petition number 628,987, filed October 25, 1945, by August Hol (Merck Chemicals sponsor), the original work on development of cows'-milk vaccine, called "Immune Milk," was performed at the University of Minnesota, School of Biochemistry, under the direction of the patent assignees. (Porter: Biological Abstracts 1953, p. 951, par. 10, 185). In August, 1951, Dr. Porter, then "working on his doctoral thesis, suggested the possibility of manufacturing antibodies in the cow's udder by infusion of antigen into the udder of a lactating cow."

The earliest patent seems to be that of patent number 587,849, December 1, 1959 in Canada by William E. Petersen of St. Paul, Minnesota and Berry Campbell of Monrovia, California. The International Association on Immunity was founded in 1963 by Herbert Struss, Ph.D., William E. Peterson, Ph.D., and Robert Meade. That Association published three issues of Journal of Immune Milk. In the first journal Campbell and Peterson summarized "The Current Picture," a resume of the history of knowledge of immunity up through 1961; and that issue, as well as the two following, published patents found in footnotes, as well as articles by others. Intent was, according to Dr. Struss,31 also editor of the Journal, to follow up with an issue on Russian research as well as that on viruses by Dr. Mitchell, D.V.M., Ph.D. in Canada. Dr. Mitchell had performed almost identical work to that of Peterson but on viruses, especially Newcastle's disease, and, according to Dr. Struss, his work was "just fantastic."

Herbert Struss, Ph.D.31 published "Immune Milk Treatment of Rheumatoid Arthritis -- Review" June 1964.


On April 2, 1968, patent number 3,376,198, "Method of Producing Antibodies in Milk," was granted to William E. Petersen, St. Paul, Minnesota and Berry Campbell, Monrovia, California, assigned to Collins Products, Inc., Waukon, Iowa.

Gregory B. Wilson and Gary V. Paddock, both of Mount Pleasant, North Carolina, were granted patent number 4,816,563, "Process for Obtaining Transfer Factor From Colostrum, Transfer Factor So Obtained and Use Thereof," March 28, 1989.

Robert A. Collins and Philip F. Weighner of Waukon, Iowa, were granted patent number 4,843,065 June 27, 1989 for "Method of Producing Products for Use in the Treatment of Bacterial and/or Virus Infections."

Robert A. Collins of Waukon, Iowa was granted patent number 5,102,669; April 7, 1992 for "Method of Producing Remedies and Products of the Method."

Giancarlo Pizzi, Caterina De Vinic and H. Hugh Fudenberg published "Transfer Factor in Malignancy," Progress in Drug Research, Vol. 42, in 1993. This was a joint paper by S. Orsola-Malpighi Hospital, Bologna, Italy, and NeuroImmuno Therapeutics Research Foundation, Spartanburg, South Carolina.

H. Hugh Fudenberg, Ph.D. and Giancarlo Pizzi, Ph.D. have summarized a great deal of their own original research, "Transfer Factor 1993: New Frontiers" in Progress in Drug Research, Vol. 42 on behalf of the NeuroImmuno Therapeutics Research Foundation,
Editorial

Perry A. Chapdelaine, Sr.
This newsletter and four earlier issues have serialized "Universal Oral Vaccine: The Immune Milk Saga!" It may seem like a lot of words for treatments that are not widely known, and perhaps difficult to obtain. So, why did Anthony di Fabio travel more than 7,500 miles (4,500 by automobile) just to chase down the facts reported?

The "miracle" of colostrum has been known for several generations. It seems as though "everyone and his uncle," is touting, and has touted, the great benefits of colostrum, and colostrum is sold everywhere: veterinary supply stores, health food stores, pyramid marketing schemes, special preparations with herbs, and so on.

Well, if it's so marvelous, and also so widely known, then why do so many continue to suffer from allergies, cancer, arthritis, and so on? Why don't the afflicted simply purchase the stuff either from a health food store, or in response to an advertisement or other marketing scheme? And then, why aren't they miraculously cured?

Finding the answers to these questions constituted di Fabio's long search, and also revealed a great deal of misinformation about colostrum.

America seems to be the great depository and home for medical nostrums, and other frontier medicines. One branch of these nostrums grew into our internationally allied pharmaceutical companies that dominate the nature of medical practices through patented drugs. The other branches, often unpatented -- but not always -- is reflected by hundreds of thousands of "natural" remedies. Colostrum, and its products are representative of this branch, but can also be found on both sides of the nostrum spectrum.

Anthony di Fabio discovered that there's a serious problem when purchasing colostrum from many sources, no matter how much a particular product is touted to be effective. The ingredients in a particular brand label have not been designed by the cow to be specific against the microorganism that is causing the disease or affliction in the buyer! Among hundreds of millions, nay, trillions of different inimical microorganisms, can one be sure that the over-the-market colostrum contains the ingredients that were especially designed by the cow to fight a particular disease caused by a specific strain of microorganism or allergy caused by a particular pollen?

Oh, sure, it contains another thousand or so immune enhancing factors some of which might be needed by the individual purchaser, but so do a lot of other natural foods such as carrots, beets, cabbage, broccoli, etc., as well as a large variety of herbs. Who shall say which among these choices is most immune enhancing for a particular individual?

Home-grown utilizations, represented by dairymen Herb Saunders and initially researched by Herb Strauss, Ph.D. and University of Minnesota scientists, really got specific to the individual patient. By inserting patient's blood in the cow's eistern, the cow had no choice but to develop exactly the right complement and antibodies needed for any infection, or combination of infections or allergies, as a number of happy patients have learned. (Our past newsletters: Spring 2000, Summer 2000 issues of "Universal Oral Vaccine: The Immune Milk Saga!")

Another most serious problem is this: Suppose a cow has been challenged at just the right time with a form of Staphylococcus that creates a specific infectious disease. By the time the colostrum has been shipped, stored and degraded over time throughout trucking, hot warehousing, and other marketing practices, one would be lucky indeed to find any viable complement, the substance necessary to fight that particular infection. As it is with important Lactobacillus acidophilus, I suspect that these proteins can be degraded easily without careful, gentle handling and refrigeration.

Anthony di Fabio found much outright huckstering based on exaggerations and sometimes misunderstandings by those with otherwise good intentions, and, surprisingly, found also a great deal of solid, evidence-based research on products sold world-wide (Our newsletters: Winter 2000 & Spring 2000 issues, "Universal Oral Vaccine: The Immune Milk Saga!"). This solid research actually began at the University Minnesota and extended throughout the 1960's by several groups. Had the FDA and the Department of Agriculture played square, these folks possibly would have furnished cheap easy-to-use supplements that would have considerably decreased the growth of the patent medicine empire.

One of the most astounding outcomes from this early research period came through studies demonstrating that homeopathic remedies made from properly prepared colostrum would cure cattle of a variety of diseases, and would also protect mice from otherwise deadly pathogens. (Our newsletters: See this issue's reference 44 in "Universal Oral Vaccine: The Immune Milk Saga!")

If these studies are true, and also the studies of Philip Derse (Derse & Schroeder Associates; Our newsletter: Summer 2000 issue) demonstrating that immune enhancing agents called transfer factors and complement can be obtained from properly challenged cow's milk itself when also properly treated, that it can be freeze dried and packaged safely, then the technology already exists to create an abundance of extremely cheap antigen-specific colostrum. It can be safely shipped throughout the world, and can be made into homeopathic remedies that would lessen humanity's reliance on profit-hungry pharmaceutical monopolies.

To some extent, the second phase was picked up by Stolle Company as well as Quantum Research, Inc. -- and I'm sure others. (Our newsletter: Summer 2000 and this issue).

Stolle Company approached the problem in a way that permitted

(continued on page 7)
Spartanburg, South Carolina. Therein it is concluded that bovine colostrum milk is almost the ideal source for obtaining protective factor.


Additional Scientific Studies

Cured or protected according to referenced patents were mice, cows, goats, chickens and pigs.

Covered by Complement Patents: For allergy prevention, one can use a mixture of hair (cats, dogs, cattle), making a vaccine. (Many milk-producing farmers become allergic to cow’s hair.) Other allergens, such as pollen, can also be introduced, such that many other allergies can be beneficially affected.

Covered by Complement Patents: It’s also good for chickenpox, cold sores, genital herpes, Cryptococcosis sp., and for anti-inflammatory conditions, as it is heavy with complement and anti-complement (C3B), substances that assist in the destruction of invasive organisms.

Covered by Complement Factors: It is currently being used for treatment against candidiasis.

Covered by Complement Factors: Early work using the described principle for Rheumatoid Arthritis involved dead staphylococcus and streptococcus organisms injected as antigens into the cow’s cistern. The success results strongly support the theory of an infectious character of Rheumatoid Arthritis. As many forms of Rheumatoid Diseases and related diseases seem to have an infectious and/or allergic component, such as ankylosing spondilitis, candidiasis, Crohn’s disease, fibrositis, fibromyalgia, food allergies, rhinitis, and so on, this form of protection may be all-inclusive, inexpensive, and all-important.

Complement Factors: According to one spokesperson, "The homeopathic remedy derived from this process has been found useful for various forms of arthritis.

Beta-lactoglobulin: In work supported by the National Institutes of Health and by Philip Morris Cos., "A modified version of a protein extracted from whey blocked the AIDS virus from infecting cells in the test tube," according to Dr. Robert Neath, head of the laboratory of Biochemical Virology at the Lindsley F. Kimball Research Institute of the New York Blood Center.

Scientists modified a whey protein called beta-lactoglobulin to produce a substance called B69, which they discovered latched onto a protein structure called CD4 on the surface of cells. This prevented the AIDS virus from using CD4 as an entryway into the cells.

(Dr. Jeffrey Laurence, an AIDS researcher at Cornell Medical College in New York, cautioned that HIV can infect some cells without using the CD4 gateway. A growing number of scientists and physicians have come to doubt the existence of a virus having the deadly characteristics attributed to HIV, but believe that AIDS symptoms point to an overwhelmed immune system, not to a specific virus.)

References

3. Personal letter from Berkely Bedell July 18, 1994; also personal interview.
6. Personal interview with, and correspondence from a scientist who chooses not to be identified.
17. Personal communication with Herbert Saunders, Calvin Johnson, Atty. Bob Collins, Paul Weigher, M.S. patient, Herbert Strauss, Ph.D., Diane Miller, Atty.
Universal Oral Vaccine: The Immune Milk Saga

NY, May-June 1960, p. 6.

29. Taken from instructions and capsule labels furnished by Herbert Struss, Ph.D. used in the original studies and also from article, Cyril M. Smith, M.D., "Immune Milk in the Treatment of the Rheumatoid Arthritis Syndrome," Journal of Immune Milk, Volume I, Number 1, International Association on Immunity, 2651 University Avenue, St. Paul, MN, June 1964.
30. Paul K. Pybus, Dr., The Hersheiser Effect, The Arthritis Fund/The Rheumatoid Disease Foundation, 5106 Old Harding Road, Franklin, TN 37064.
31. Symios.com Homepage (www.symiotics.com)
34. The U.S. District Court for the District of Columbia: Impro Products Co., Inc., vs John R. Block Secretary of the United States (Civil No. 81-1284, July 9, 1982; July 28, 1982; Sept 2, 1982.)
36. Patents used as source materials.
36a. U. S. Patent Office October 25, 1945 628,987
36b. Canadian Patent Office December 1, 1959 587,849
36d. U. S. Patent Office April 18, 1981 4,284,623
36e. U. S. Patent Office September 6, 1983 4,402,938
36g. U. S. Patent Office June 27, 1989 4,843,065 (referred to on page 8)
36i. U. S. Patent Office April 7, 1992 5,102,669

Those who are interested in receiving copies of the above may order them from the U.S. Patent Office.
37. Other Important Papers Used as Source Material:

United States

Collins

Date of Patent: Apr. 7, 1992

METHOD OF PRODUCING REMEDIES AND PRODUCTS OF THE METHOD

<table>
<thead>
<tr>
<th>Type of raw product used to produce</th>
<th>Treatment</th>
<th>Pseudomonas Challenge</th>
<th>Alive</th>
<th>Sick</th>
<th>Dead</th>
</tr>
</thead>
<tbody>
<tr>
<td>2nd mother</td>
<td>Dosage</td>
<td>ml</td>
<td>ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NON USED**</td>
<td>WATER</td>
<td>25 x 10^6</td>
<td>1</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>NON USED</td>
<td>2mg eq.</td>
<td>300</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>COLOSTRUM A 3x</td>
<td></td>
<td>&quot;</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>COLOSTRUM A 6x</td>
<td></td>
<td>&quot;</td>
<td>3</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>MILK C 3x</td>
<td></td>
<td>&quot;</td>
<td>1</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>MILK C 6x</td>
<td></td>
<td>&quot;</td>
<td>3</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>NON USED*</td>
<td>Water (one mouse)</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dosage Varied</th>
<th>TEST 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NON USED**</td>
<td>WATER</td>
</tr>
<tr>
<td>NON USED</td>
<td>2mg eq.</td>
</tr>
<tr>
<td>COLOSTRUM</td>
<td>1cc A 3x</td>
</tr>
<tr>
<td>COLOSTRUM</td>
<td>.5cc A 3x</td>
</tr>
<tr>
<td>MILK C 3x</td>
<td>1cc C 3x</td>
</tr>
<tr>
<td>MILK C 3x</td>
<td>.5cc C 3x</td>
</tr>
<tr>
<td>MILK C 3x</td>
<td>.25cc C 3x</td>
</tr>
</tbody>
</table>

4 mice per group
390° = our positive control
A = Colostrum used as a raw material to produce the second mother
C = Milk used as raw material to produce the second mother
** = Control
Tests conducted at Dare Schroeder Laboratories, Madison, Wisconsin

High Somatic Cell Count (SCC) March 1987

<table>
<thead>
<tr>
<th>Cow</th>
<th>SCC on March 5</th>
<th>TREATMENT</th>
<th>SCC on March 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>66</td>
<td>&gt;1,000,000</td>
<td>2-4cc MT on feed</td>
<td>&lt;200,000</td>
</tr>
<tr>
<td>65</td>
<td></td>
<td></td>
<td>&lt;200,000</td>
</tr>
<tr>
<td>60</td>
<td></td>
<td></td>
<td>&gt;1,000,000</td>
</tr>
<tr>
<td>82</td>
<td></td>
<td></td>
<td>= 1,000,000</td>
</tr>
<tr>
<td>172</td>
<td></td>
<td></td>
<td>&gt;200,000</td>
</tr>
<tr>
<td>146</td>
<td></td>
<td></td>
<td>&lt;200,000</td>
</tr>
<tr>
<td>69</td>
<td></td>
<td></td>
<td>&lt;200,000</td>
</tr>
<tr>
<td>173</td>
<td></td>
<td></td>
<td>&lt;200,000</td>
</tr>
<tr>
<td>200</td>
<td></td>
<td></td>
<td>&lt;200,000</td>
</tr>
<tr>
<td>136</td>
<td></td>
<td></td>
<td>&lt;200,000</td>
</tr>
<tr>
<td>124</td>
<td></td>
<td></td>
<td>&lt;200,000</td>
</tr>
<tr>
<td>150</td>
<td></td>
<td></td>
<td>&lt;200,000</td>
</tr>
</tbody>
</table>

(continued on page 7)
Universal Oral Vaccine: The Immune Milk Saga

(continued from page 6)

Cow | June 1987 | Treatment | SCC on June 22
--- | --- | --- | ---
82 | >1,000,000 | 5cc MT, 2-4 times | <200,000
52 | " | 5cc MT, 2-4 times | <200,000
154 | " | 5cc MT, 2-4 times | <200,000
151 | " | 5cc MT, 2-4 times | <200,000
37 | " | 5cc MT, 2-4 times | <600,000
196 | " | 5cc MT, 2-4 times | 1,000,000
120 | " | 5cc MT, 2-4 times | <200,000
144 | " | 5cc MT, 2-4 times | <200,000
464 | " | 5cc MT, 2-4 times | <200,000
60 | " | 5cc MT, 2-4 times | 1,000,000
61 | " | 5cc MT, 2-4 times | <200,000
75 | " | 5cc MT, 2-4 times | <200,000

Note: Only one cow, #60, repeated in the second list in June. The necessity of reducing a high cell count in a dairy herd is essential in selling milk. Herds with cell counts over one and one-half million are prohibited from selling their milk on the market.

RESULTS

<table>
<thead>
<tr>
<th>Cow Identification</th>
<th>Condition</th>
<th>Treatment Amount</th>
<th>Number of Treatments</th>
<th>Hours to Return to Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>#11RN</td>
<td>Clinical</td>
<td>10cc IU*</td>
<td>2</td>
<td>36</td>
</tr>
<tr>
<td>#33RN</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>2</td>
<td>36</td>
</tr>
<tr>
<td>#7RN</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>3</td>
<td>48</td>
</tr>
<tr>
<td>#20JS</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>3</td>
<td>48</td>
</tr>
<tr>
<td>#38JS</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>2</td>
<td>36</td>
</tr>
<tr>
<td>#39JS</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>1</td>
<td>24</td>
</tr>
<tr>
<td>#53JS</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>2</td>
<td>60</td>
</tr>
<tr>
<td>#57JS</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>1</td>
<td>48</td>
</tr>
<tr>
<td>#79TH</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>4</td>
<td>48</td>
</tr>
<tr>
<td>#14TH</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>3</td>
<td>48</td>
</tr>
<tr>
<td>#23JS</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>2</td>
<td>24</td>
</tr>
<tr>
<td>#84JS</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>1</td>
<td>24</td>
</tr>
<tr>
<td>REDJS</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>2</td>
<td>36</td>
</tr>
<tr>
<td>WHITEJS</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>2</td>
<td>24</td>
</tr>
<tr>
<td>#180CT</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>3</td>
<td>Failed</td>
</tr>
<tr>
<td>#121CT</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>4 + 3 orally</td>
<td>Failed</td>
</tr>
<tr>
<td>#R23CT</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>2</td>
<td>Partial</td>
</tr>
<tr>
<td>#46JA</td>
<td>Clinical</td>
<td>10cc IU</td>
<td>4</td>
<td>Failed</td>
</tr>
</tbody>
</table>

There is a great economic advantage in getting clinical cows back to normal without the use of antibiotics. This is due to the milk throwaway required when antibiotics are given a lactating dairy cow.

*Inter udder

45. Jesse A. Stoff, M.D., The Use of Dialyzable Bovine Colostrum Extract in Conjunction With a Holistic Treatment Model for Natural Killer Cell Stimulation


How to Receive Our...
PHYSICIAN AND SCIENTIST ADVISORY LIST
Send a legal size, self-addressed, stamped envelope to The Arthritis Trust of America®, 7111A Sweetgum Road, Fairview, TN 37062-9384, and ask for our latest Physician and Scientist Advisory list. Or, go to our website at www.arthritistrust.org.

When requesting our Physician and Scientist Advisory list, while it is not necessary to donate $2, a donation of that size or greater would help us defray the cost of this service.

Editorial

(continued from page 4)

them to utilize the New Zealand Dairy Board production facilities. They inoculated cows and drained off the desired molecules without interrupting the flow of normal dairy products.

Quantum Research, Inc., in a different vein, represents an approach that has clearly shown successful and amazing clinical results for a wide spectrum of degenerative diseases, cancer to chronic fatigue syndrome and other afflictions.

Through periodic laboratory measures of the activity of natural killer cells, their physician associates have been able to correlate increased activity with decrease in the disease and its symptoms. (Please note: this is not a natural killer cell count, but rather a measure of activity of the killer cells already present in the patient.) The tests and stimulating supplement are not inexpensive, and results may take a year or so to gradually demonstrate effectiveness in some immune-weakened cases — but, considering the alternatives, this is indeed a "miraculous" result from colostrum.

References are often boring and uninteresting, unless you happen to be in need of several of them. In this newsletter, we’ve included all the references to our five part paper so that you can see for yourself the tremendous amount of work that has been accomplished with colostrum, as well as results of the studies using homeopathic preparations for challenged mice, and sick cows, reference 44.

While you’re at it, also read the "Background and Summary" at the beginning of the references.

The world is immersed in colostrum products and claims for these products. Some of these claims are valid, and many are simply exaggerated, or based on unreliable testimony. A few are superb, backed up by legitimate results.

"Universal Oral Vaccine: The Immune Milk Saga!" is not a definitive article, but does seem to sample a broad spectrum of activity!

By the way: One family, on reading our newsletter, and lacking a source for properly prepared colostrum, but having access to a dairy cow, contacted one of the scientists we’ve reported, and has then been able to prepare their own specific colostrum by injecting their own blood into a cow just prior to calving. They’ve achieved remarkable results in a short time period, apparently solving their cancer problem.

[Box]
Executive Director, United Kingdom

Rex Newnham, Ph.D., D.O., N.D. was born in 1920 in New Zealand and then moved on to Australia. He served six years war service in the Middle East and New Guinea, rising to rank of Captain. His service work was to ensure safety of ammunition and bomb disposal.

After WWII, he married and started the study of medicine in Melbourne, Australia. He had to quit after 2½ years, working as a carpenter building houses.

In 1950 Dr. Newnham taught science, chemistry, agricultural botany and soil science, while also studying for a science degree majoring in botany.

In 1964 he found that boron would heal his arthritis, and also that of others.

He retired from teaching in 1978 and studied naturopathy, homeopathy and nutrition, setting up practice in Melbourne, Australia, where he organized double blind hospital trials (Royal Melbourne Hospital) to test the boron tablets on others. Because of hostility by the patented medicine industry (pharmaceutical companies) toward his non-patented discoveries, Dr. Newnham moved to New Zealand from whence he also started his epidemiological research, traveling nine times around the world to test and correlate minerals, including boron, in soils and relate them to degree of arthritis in the related population.

Having established a significant positive correlation between lack of boron in soil and food plants grown in the same soil, and increasing incidence of arthritis, Dr. Newnham moved to England, earned a Ph.D. in nutrition in London in 1990, and now serves to guide people with arthritis and other diseases. (See Dr. Newnham’s book, Away With Arthritis, available through this foundation, and the article “Boron and Arthritis” in our list of articles.) His findings have been accepted worldwide by the vast majority of physicians dedicated to the practice of complementary and alternative medicine.

Dr. Newnham has been a consultant for the US Department of Health and Human Services, and also for NASA. He is also the founder and president of one of our sister organizations, the Arthritis and Rheumatism Natural Therapy Research Association (ARNTRA), located in England. In this capacity, he’s enjoys helping folks with arthritis and other degenerative diseases.

Published quarterly by the Board of Directors

Board Members

Canadian & United States of America
Carolyn Blount, R.N.
President Emeritus
Jack M. Blount, M.D.
Chairman and Chief Medical Advisor
Perry A. Chapdelaine, Sr., M.A.
Executive Director/Secretary
Ron Davis, M.D.
Member
Nancy Huggins
Treasurer
Harold Hunter, M.S.
Vice-Chairman
Lucelyn Verano-Chapdelaine
President

Canadian
Paul Jaconello, M.D.

England
Rex E. Newnham, D.O., N.D., Ph.D.
Arthritis and Rheumatism Natural Therapy Research Association (ARNTRA)
Cracoe House Cottage, Cracoe, Nr. Skipton
North Yorkshire BD23 6LB; Phone 01 756 730 240

Republic of South Africa
Alma Gouws
The Rheumatoid Disease Foundation Trust
PO Box 10237, Ashwood, 3605 KZN, S. A.
(031) 700-4707

The Arthritis Trust is a project of
The Roger Wyburn-Mason & Jack M. Blount Foundation
for the Eradication of Rheumatoid Disease
Tax Exemption approved by
The United States Internal Revenue Service
& The Republic of South Africa, Non-profit Canada and England
Chartered in Canada, Republic of South Africa, England & United States (Tennessee)
Editor-in-Chief: Perry A. Chapdelaine, Sr.
Fax/phone (615) 799-1002
Internet: http://www.arthritistrust.org (also *.com; *.net)
E-mail: administration@arthritistrust.org

How to Receive Our . . .

PUBLICATIONS LIST

Send a legal size, self-addressed, stamped envelope to The Arthritis Trust of America®, 7111A Sweetgum Road, Fairview, TN 37062-9384, and ask for our latest Publications list. Or, go to our website at www.arthritistrust.org.

When requesting our Publications list, while it is not necessary to donate $2, a donation of that size or greater would help us defray the cost of this service.

The Arthritis Trust is a Project of The Roger Wyburn Mason and Jack M. Blount Foundation for the Eradication of Rheumatoid Disease
United States: 7111 A Sweetgum, Road, Fairview, TN 37062-9384 • Canada: Fourth Floor, 300 March Road, Kanata, ON K2K 2E2